Genmab

US · GMAB #860 by market cap Listed 2019

36.65 -1.15 -3.04%

Live - 5344 symbols - heartbeat 481s ago · 2026-10-08 07:31

Pre-market 35.65 -2.73%

After-hours 36.65 0.00%

Overnight 35.73 -2.51%

Market cap: 22.54B
P/E (TTM): 28.97
P/B: 3.78
EPS: 1.54
Div yield: 0.00%
52W pos: 79%

Reader sentiment Are you bullish or bearish on GMAB?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Financial Health how this is computed

Good

Altman Z-Score is 3.12, above the 3.0 "safe zone" threshold.
Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.

Revenue annual, last 8 years

Latest year +19.19% YoY

Margins

Gross margin: 93.60%
Operating margin: 33.60%
Net margin: 25.89%

Key ratios & quality

Enterprise value: 26.11B
PEG ratio: 4.10
Altman Z-Score: 3.12

PEG uses trailing P/E against the 3-year net income growth rate (7.06%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.

Income statement

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Revenue	463.40M	804.48M	1.67B	1.28B	2.09B	2.39B	3.12B	3.72B
Gross profit	--	--	--	1.28B	2.09B	2.36B	2.98B	3.48B
Selling & admin expenses	32.78M	51.27M	109.25M	195.32M	385.15M	478.00M	549.00M	626.00M
Research & development	219.21M	357.71M	518.50M	636.50M	800.53M	1.11B	1.41B	1.61B
Operating profit	211.40M	395.49M	1.04B	449.55M	902.00M	772.00M	1.02B	1.25B
Pretax profit	246.94M	428.63M	975.84M	596.46M	999.58M	817.00M	1.33B	1.20B
Tax	21.45M	103.90M	189.42M	146.30M	214.89M	186.00M	193.00M	241.00M
Net profit	225.50M	324.73M	786.43M	450.16M	784.70M	631.00M	1.13B	963.00M
Basic EPS	0	1	1	1	1	1	2	2
Diluted EPS	0.36	0.51	1.19	0.68	1.19	0.96	1.75	1.54

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Revenue	715.00M	925.00M	1.02B	1.06B	896.00M	1.16B
Gross profit	673.00M	868.00M	964.00M	977.00M	831.00M	1.07B
Selling & admin expenses	126.00M	144.00M	148.00M	208.00M	166.00M	205.00M
Research & development	359.00M	364.00M	357.00M	526.00M	440.00M	459.00M
Operating profit	188.00M	360.00M	459.00M	243.00M	225.00M	407.00M
Pretax profit	244.00M	423.00M	482.00M	55.00M	74.00M	295.00M
Tax	49.00M	87.00M	81.00M	24.00M	21.00M	-8.00M
Net profit	195.00M	336.00M	401.00M	31.00M	53.00M	303.00M
Basic EPS	0	1	1	0	0	0
Diluted EPS	0.31	0.54	0.65	0.05	0.08	0.49

Balance sheet

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Total current assets	1.14B	2.09B	3.11B	3.46B	4.06B	4.91B	3.90B	2.89B
Cash & ST investments	935.38M	1.64B	2.66B	2.94B	3.21B	4.17B	2.95B	1.72B
Inventory	--	--	--	--	0	8.00M	9.00M	18.00M
Total assets	1.30B	2.27B	3.49B	3.75B	4.33B	5.23B	6.41B	12.87B
Total current liabilities	68.02M	140.63M	207.10M	238.71M	262.38M	368.00M	744.00M	1.43B
Short-term debt	--	3.90M	6.94M	9.44M	10.65M	13.00M	13.00M	291.00M
Long-term debt	--	--	--	--	--	--	--	5.00B
Total liabilities	68,475,943.04	164,314,392.20	334,206,037.53	370,085,632.73	408,324,817.57	545,000,000.00	1,277,000,000.00	7,026,000,000.00
Total equity	1.23B	2.11B	3.16B	3.38B	3.93B	4.69B	5.14B	5.85B
Retained earnings	-30.33M	319.33M	1.17B	1.53B	2.13B	2.74B	3.39B	4.10B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Total current assets	4.04B	3.91B	4.47B	2.89B	2.57B	2.80B
Cash & ST investments	3.23B	2.90B	3.41B	1.72B	1.52B	1.50B
Inventory	12.00M	13.00M	14.00M	18.00M	21.00M	18.00M
Total assets	6.59B	6.46B	7.02B	12.87B	12.38B	12.52B
Total current liabilities	756.00M	629.00M	741.00M	1.43B	1.18B	1.14B
Short-term debt	14.00M	16.00M	16.00M	291.00M	293.00M	312.00M
Long-term debt	--	--	--	5.00B	4.93B	4.84B
Total liabilities	1,290,000,000.00	1,162,000,000.00	1,270,000,000.00	7,026,000,000.00	6,694,000,000.00	6,558,000,000.00
Total equity	5.30B	5.30B	5.75B	5.85B	5.68B	5.96B
Retained earnings	3.54B	3.60B	4.03B	4.10B	4.09B	4.42B

Cash flow

Line item	2018	2019	2020	2021	2022	2023	2024	2025
Operating cash flow	155.49M	198.80M	1.06B	339.18M	563.05M	1.07B	1.13B	1.19B
Depreciation & amortization	13.48M	20.84M	42.81M	37.75M	52.10M	43.00M	60.00M	71.00M
Free cash flow	82.26M	182.16M	1.01B	300.82M	517.42M	1.02B	1.08B	1.13B
Dividends paid	--	--	--	--	--	--	--	--
Stock buybacks / issuance	-22.37M	580.65M	0	-68.05M	-130.69M	-81.00M	-560.00M	5.07B
Ending cash balance	81.65M	532.52M	1.20B	1.36B	1.42B	2.20B	1.38B	1.72B

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
Operating cash flow	287.00M	62.00M	536.00M	301.00M	3.00M	51.00M
Depreciation & amortization	16.00M	16.00M	18.00M	21.00M	29.00M	26.00M
Free cash flow	257.00M	52.00M	534.00M	288.00M	-2.00M	48.00M
Dividends paid	--	--	--	--	--	--
Stock buybacks / issuance	0	-406.00M	-24.00M	5.50B	-96.00M	0
Ending cash balance	1.62B	1.30B	1.76B	1.72B	1.52B	1.50B

Returns & efficiency

Line item	2018	2019	2020	2021	2022	2023	2024	2025
ROE %	20.15	19.48	29.87	14.01	21.69	14.95	22.30	17.56
ROA %	19.11	18.21	27.28	12.64	19.61	13.47	18.82	10.00
ROIC %	19.37	18.20	28.55	13.12	20.34	12.25	19.66	10.90
5-year avg ROE %	23.50	23.06	23.73	20.85	20.95	19.85	20.57	18.10
EBIT margin %	53.30	53.41	58.49	47.11	48.35	34.38	43.13	34.01
FCF / sales %	17.77	22.64	60.59	23.30	24.63	42.52	34.69	30.40
Current ratio	16.74	14.88	15.00	14.50	15.48	13.35	5.24	2.02
Quick ratio	16.74	14.88	15.00	14.50	15.48	13.33	5.23	2.01
Debt / assets	0.00	1.20	1.51	1.73	1.98	2.18	2.25	42.15
LT debt / equity	--	1.10	1.45	1.64	1.92	2.15	2.55	87.82
Interest coverage	3,866.64	409.43	591.40	307.38	336.00	209.78	77.37	20.74
Revenue CAGR (3Y) %	40.81	46.29	63.68	40.36	37.42	12.67	34.55	21.23
Net income CAGR (3Y) %	26.33	24.57	64.12	25.91	34.19	-7.08	36.03	7.06
FCF CAGR (3Y) %	47.20	63.49	61.20	54.06	41.62	0.15	53.22	29.78

Line item	2025-03	2025-06	2025-09	2025-12	2026-03	2026-06
ROE %	21.95	25.24	27.45	17.56	14.96	14.00
ROA %	18.46	20.49	22.30	10.00	8.66	8.30
ROIC %	19.53	23.00	25.18	10.90	10.44	10.90
5-year avg ROE %	--	--	--	--	--	--
EBIT margin %	41.45	43.34	47.37	34.01	30.81	28.44
FCF / sales %	34.79	28.23	33.54	30.40	22.35	21.01
Current ratio	5.34	6.22	6.03	2.02	2.18	2.46
Quick ratio	5.32	6.20	6.01	2.01	2.17	2.44
Debt / assets	2.17	2.29	2.02	42.15	43.24	42.13
LT debt / equity	2.44	2.49	2.19	87.82	89.02	83.28
Interest coverage	72.78	59.53	69.17	20.74	7.15	4.37
Revenue CAGR (3Y) %	--	--	--	--	--	--
Net income CAGR (3Y) %	--	--	--	--	--	--
FCF CAGR (3Y) %	--	--	--	--	--	--

✦ Quant Revenue Concentration how this is computed

Lead segment, long tail

DARZALEX is the largest reported line at 64.42% of revenue, across 8 reported segments.
Net product sales follows at 12.55%, so the top line still matters most but isn’t the whole story.

Revenue breakdown most recent period

Business

DARZALEX64.42%

Net product sales12.55%

Kesimpta12.38%

Other4.16%

TEPEZZA2.68%

Collaboration revenue1.90%

Reimbursement revenue1.04%

Milestone revenue0.87%

Quote time 2026-10-08 07:31:12 · For reference only, not investment advice and not tailored to your situation.